Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”
Angelo Antonini,
K. Ray Chaudhuri,
Josefa Domingos,
Joohi Jimenez-Shahed,
Jack Wright,
Connie H. Yan,
Ali Alobaidi,
Lars Bergmann,
Koray Onuk,
Linda Harmer,
Irene A. Malaty
Affiliations
Angelo Antonini
Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua
K. Ray Chaudhuri
Parkinson Foundation Centre of Excellence, King’s College Hospital and King’s College
Josefa Domingos
European Parkinson’s Disease Association (EPDA)
Joohi Jimenez-Shahed
Department of Neurology, Icahn School of Medicine at Mount Sinai
Jack Wright
Adelphi Real World
Connie H. Yan
AbbVie Inc
Ali Alobaidi
AbbVie Inc
Lars Bergmann
AbbVie Inc
Koray Onuk
AbbVie Inc
Linda Harmer
AbbVie Inc
Irene A. Malaty
Fixel Institute for Neurological Diseases, University of Florida
Abstract The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson’s Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.